Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for â¥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Keywords: استعداد; apremilast; clinical trial; ESTEEM; phosphodiesterase 4 inhibitor; psoriasis; psoriatic arthritis; safety; AE; adverse event; EAIR; exposure-adjusted incidence rate; ESTEEM; Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; GI;